<p>Radiolabeled PEG-Lip (open bar), PRP-PEG-Lip (light grey bar), RGD-PEG-Lip (dark grey bar), or Dual-PEG-Lip (closed bar) were injected into Colon26 NL-17-bearing mice (<i>n</i> = 5) via a tail vein at 10 days after the tumor inoculation. At 24 h after the injection, the radioactivity in each organ was determined. Data are shown as a percent of the injected dose per 100 mg tissue and SD. Significant differences: *, <i>P</i><0.05; **, <i>P</i><0.01; ***, <i>P</i><0.001.</p
<p>Subcutaneous α<sub>v</sub>β<sub>6</sub>-positive H2009 (panel A) or α<sub>v</sub>β<sub>6</sub>-ne...
<p>Subcutaneous α<sub>v</sub>β<sub>6</sub>-positive H2009 tumors were established in the flank of NO...
<p>Tumor-to-contralateral brain ratios for <sup>111</sup>In-doxorubicin liposomes in the GBM-bearing...
<p>Either neutravidin-cetuximab, at a dose of 20 µg of antibody, or PBS was injected i.p. to the mic...
<p>DiI fluorescence-labeled PEG-Lip (a–c), PRP-PEG-Lip (d–f), RGD-PEG-Lip (g–i) or Dual-PEG-Lip (j–l...
[[abstract]]Nanoliposomes are useful carriers in drug delivery. Radiolabeled nanoliposomes have pote...
[[abstract]]Nanoliposomes are useful carriers in drug delivery. Radiolabeled nanoliposomes have pote...
<p>The conventional liposomes (CL) and galactosylated liposomes (Gal-lipo) were labeled by DiR. Each...
<p>Biodistribution of <sup>64</sup>Cu-CB-TE1A1P-LLP2A in 5TGM1 s.c. tumor mice (black bars). The ope...
<p>Either targeted liposomal DXR or non-targeted liposomal DXR was injected i.v. at a dose of 2 mg/k...
<p>(a) Time radioactivity curves in blood. (b) Time radioactivity curves in tumors. (c) Tumor to blo...
<p>Subcutaneous α<sub>v</sub>β<sub>6</sub>-negative H460 tumors were established in the flank of NOD...
[[abstract]]PEGylated liposomes are important drug carriers for nanomedicine cancer therapy. PEGylat...
<p>The percentage of the injected dose per gram of tissue (%ID/g) ± SD in the different organs, at t...
[[abstract]]PEGylated liposomes are important drug carriers for nanomedicine cancer therapy. PEGylat...
<p>Subcutaneous α<sub>v</sub>β<sub>6</sub>-positive H2009 (panel A) or α<sub>v</sub>β<sub>6</sub>-ne...
<p>Subcutaneous α<sub>v</sub>β<sub>6</sub>-positive H2009 tumors were established in the flank of NO...
<p>Tumor-to-contralateral brain ratios for <sup>111</sup>In-doxorubicin liposomes in the GBM-bearing...
<p>Either neutravidin-cetuximab, at a dose of 20 µg of antibody, or PBS was injected i.p. to the mic...
<p>DiI fluorescence-labeled PEG-Lip (a–c), PRP-PEG-Lip (d–f), RGD-PEG-Lip (g–i) or Dual-PEG-Lip (j–l...
[[abstract]]Nanoliposomes are useful carriers in drug delivery. Radiolabeled nanoliposomes have pote...
[[abstract]]Nanoliposomes are useful carriers in drug delivery. Radiolabeled nanoliposomes have pote...
<p>The conventional liposomes (CL) and galactosylated liposomes (Gal-lipo) were labeled by DiR. Each...
<p>Biodistribution of <sup>64</sup>Cu-CB-TE1A1P-LLP2A in 5TGM1 s.c. tumor mice (black bars). The ope...
<p>Either targeted liposomal DXR or non-targeted liposomal DXR was injected i.v. at a dose of 2 mg/k...
<p>(a) Time radioactivity curves in blood. (b) Time radioactivity curves in tumors. (c) Tumor to blo...
<p>Subcutaneous α<sub>v</sub>β<sub>6</sub>-negative H460 tumors were established in the flank of NOD...
[[abstract]]PEGylated liposomes are important drug carriers for nanomedicine cancer therapy. PEGylat...
<p>The percentage of the injected dose per gram of tissue (%ID/g) ± SD in the different organs, at t...
[[abstract]]PEGylated liposomes are important drug carriers for nanomedicine cancer therapy. PEGylat...
<p>Subcutaneous α<sub>v</sub>β<sub>6</sub>-positive H2009 (panel A) or α<sub>v</sub>β<sub>6</sub>-ne...
<p>Subcutaneous α<sub>v</sub>β<sub>6</sub>-positive H2009 tumors were established in the flank of NO...
<p>Tumor-to-contralateral brain ratios for <sup>111</sup>In-doxorubicin liposomes in the GBM-bearing...